Management of Idiopathic Nephrotic Syndrome in Adults: Minimal Change Disease and Focal Segmental Glomerulosclerosis

Evidence-Based Nephrology

Volumn , Issue , 2009, Pages 147-157

  Meyrier, Alain ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

INS occurring during pregnancy posing unique situation; Management of INS in adults; Plasmapheresis; Primary glomerulonephritis; Treatment of FSGS

Indexed keywords

EID: 84890974826     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303391.ch13     Document Type: Chapter

References (93)

1. Bargman JM. Management of minimal lesions glomerulonephritis:evidence-based recommendations. Kidney Int 1999; 55(Suppl 70): S3-S16.
2. Burgess E. Management of focal segmental glomerulosclerosis:evidence-based recommendations. Kidney Int 1999; 55(Suppl 70): S26-S32.
3. Conlon PJ, Lynn K, Winn MP, Quarles LD, Bembe ML, Pericak-Vance M et al. Spectrum of disease in familial focal and segmental glomerulosclerosis. Kidney Int 1999; 56: 1863-1871.
4. Ruf RG, Lichtenberger A, Karle SM, Haas JP, Anacleto FE, Schultheiss M et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004; 15: 722-732.
5. Winn MP. Approach to the evaluation of heritable diseases and update on familial focal segmental glomerulosclerosis. Nephrol Dial Transplant 2003; 18(Suppl 6): v114-v120.
6. Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 2000; 24: 349-354.
7. Huber TB, Simons M, Hartleben B, Sernetz L, Schmidts M, Gundlach E et al. Molecular basis of the functional podocin-nephrin complex:mutations in the NPHS2 gene disrupt nephrin targeting to lipid raft microdomains. Hum Mol Genet 2003; 12: 3397-3405.
8. Caridi G, Bertelli R, Di Duca M, Dagnino M, Emma F, Onetti Muda A et al. Broadening the spectrum of diseases related to podocin mutations. J Am Soc Nephrol 2003; 14: 1278-1286.
9. Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, Tong HQ et al. Mutations in ACTN4, encoding alpha-actinin-4, causes familial focal segmental glomerulosclerosis. Nat Genet 2000; 24: 251-256.
10. Komatsuda A, Wakui H, Maki N, Kigawa A, Goto H, Ohtani H et al. Analysis of mutations in alpha-actinin 4 and podocin genes of patients with chronic renal failure due to sporadic focal segmental glomerulosclerosis. Ren Fail 2003; 25: 87-93.
11. Niaudet P. Podocin and nephrotic syndrome:implications for the clinician. J Am Soc Nephrol 2004; 15: 832-834.
12. Ghiggeri GM, Carraro M, Vicenti F. Recurrent focal glomerulosclerosis in the era of genetics of podocyte proteins:theory and therapy. Nephrol Dial Transpl 2004; 19: 1036-1040.
13. Ghiggeri GM, Catarsi P, Scolari F, Caridi G, Bertelli R, Carrea A et al. Cyclosporine in patients with steroid-resistant nephrotic syndrome:an open-label carried out genetic profiling. Clin Ther 2004; 26: 1411-1418.
14. Tanawattanacharoen S, Falk RJ, Jennette JC, Kopp JB. Parvovirus B19 DNA in kidney tissue of patients with focal segmental glomerulosclerosis. Am J Kidney Dis 2000; 35: 1166-1174.
15. Moudgil A, Nast CC, Bagga A, Wei L, Nurmamet A, Cohen AH et al. Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy. Kidney Int 2001; 59: 2126-2133.
16. Li RM, Branton M, Tanawattanacharoen S, Falk RJ, Jennette JC, Kopp JB. Molecular identification of SV 40 infection in human subjects and possible association with kidney disease. J Am Soc Nephrol 2002; 13: 2320-2330.
17. Barri YM, Munshi NC, Sukumalchantra S, Abulezz SR, Bonsib SM, Wallach J et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 2004; 65: 634-641.
18. Meyrier A. Mechanisms of disease:focal segmental glomerulosclerosis. Nat Clin Pract Nephrol 2005; 1: 44-54.
19. Kerjaschki D. Caught flat-footed:podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest 2001; 8: 1583-1587.
20. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003; 83: 253-307.
21. Shankland SJ, Eitner F, Hudkins KL, Goodpaster T, d'Agati V, Alpers CE. Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease:role in podocyte proliferation and maturation. Kidney Int 2000; 58: 674-683.
22. Bariety J, Nochy D, Mandet C, Jacquot C, Glotz D, Meyrier A. Podocytes undergo phenotypic changes and express macrophagic-associated markers in idiopathic collapsing glomerulopathy. Kidney Int 1998; 53: 918-928.
23. Barisoni L, Kriz W, Mundel P, d'Agati V. The dysregulated podocyte phenotype; a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 1999; 10: 51-61.
24. Bariety J, Bruneval P, Hill G, Irinopoulou T, Mandet C, Meyrier A. Posttransplantation relapse of FSGS is characterized by glomerular epithelial cell transdifferentiation. J Am Soc Nephrol 2001; 12: 261-274.
25. Feldman RD, Campbell N, Larochelle P, Bolli P, Burgess ED, Carruthers SG et al. Development of the 1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension. CMAJ 1999; 161(Suppl 12): S1-S17.
26. Howie AJ, Pankhurst T, Sarioglou S, Turhan N, Adu D. Evolution of nephrotic-associated focal segmental glomerulosclerosis and relation to the glomerular tip lesion. Kidney Int 2005; 67: 987-1001.
27. Haas M. The glomerular tip lesion:what does it really mean? Kidney Int 2005; 67: 1188-1189.
28. Stokes BM, Markowitz GS, Lin J, Valeri AM, D'Agati VD. Glomerular tip lesion. A distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum. Kidney Int 2004; 65: 1690-1702.
29. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC, Toronto Glomerulonephritis Registry Group. Focaland segmentalglomeruloscle-rosis:definition and relevance of a partial remission. J Am Soc Nephrol 2005; 16: 1061-1068.
30. d'Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis:aworking proposal. Am J Kidney Dis 2004; 43: 368-382.
31. Meyrier AY. Collapsing glomerulopathy:expanding interest in a shrinking tuft. Am J Kidney Dis 1999; 33: 801-803.
32. Meyrier A. E pluribus unum:the riddle of focal-segmental glomerulosclerosis. Semin Nephrol 2003; 23: 135-140.
33. Korbet SM. Treatment of primary focal segmental glomerulosclerosis. J Am Soc Nephrol 2002; 62: 2301-2310.
34. Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults:presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004; 8: 2169-2177.
35. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999; 56: 2220-2226.
36. Ponticelli C, Villa M, Banfi G, Cesana B, Pozzi C, Pani A et al. Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis? Am J Kidney Dis 1999; 34: 618-625.
37. Alexopoulos E, Stangou M, Papagianni A, Pantzaki A, Papadimitriou M. Factors influencing the course and the response to treatment in primary focal segmental glomerulosclerosis. Nephrol Dial Transplant 2000; 15: 1348-1356.
38. Nakayama M, Katafuchi R, Yanase T, Ikeda K, Tanaka H, Fujimi S. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis 2002; 39: 503-512.
39. Tse KC, Lam MF, Yip PS, Li FK, Choy BY, Lai KN et al. Idiopathic minimal change nephrotic syndrome in older adults:steroid responsiveness and patternof relapses. Nephrol Dial Transplant 2003; 18: 1316-1320.
40. Huang JJ, Hsu SC, Chen FF, Sung JM, Tseng CC, Wang MC. Adult onset minimal change disease among Taiwanese:clinical features, therapeutic response, and prognosis. Am J Nephrol 2001; 21: 28-34.
41. Meyrier A. Treatment of idiopathic nephrosis by immunophillin modulation. Nephrol Dial Transplant 2003; 18(Suppl 6): v179-v186.
42. Tumlin JA, Miller D, Near M, Selvaraj S, Hennigar R, Guasch A. A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulonephritis. Clin J Am Soc Nephrol 2006; 1: 109-116.
43. Sandoz Pharma. Sanimmun use in nephrotic syndrome, part IV B, clinical experience. Study OL-9507, vol. 5, p. 7.
44. Meyrier A, Condamin MC, Broneer D. Treatment of adult idiopathic nephrotic syndrome with cyclosporine A:minimal change disease and focal-segmental glomerulosclerosis. Clin Nephrol 1991; 35: 37-42.
45. Meyrier A, Noel LH, Auriche P, Callard P. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Kidney Int 1994; 45: 1446-1456.
46. Pokhariyal S, Gulati S, Prasad N, Sharma RK, Singh U, Gupta RK. Duration of therapy for idiopathic focal segmental glomerulosclerosis. J Nephrol 2003; 16: 691-696.
47. Schwartz MM, Evans J, Bain R, Korbet SM. Focal segmental glomerulosclerosis:prognostic implication of the cellular lesion. J Am Soc Nephrol 1999; 10: 1900-1907.
48. Valeri A, Barisoni L, Appel GB, Seigle R, D'Agati V. Idiopathic collapsing focal segmental glomerulosclerosis. Kidney Int 1996; 50: 1734-1746.
49. Cameron SJ. The nephrotic syndrome and its complications. Am J Kidney Dis 1987; 10: 157-171.
50. Korbet SM. Clinical picture and outcome of primary focal segmental glomerulosclerosis. Nephrol Dial Transpl 1999; 14(Suppl 3): 68-73.
51. Nolasco F, Cameron JS, Heywood EF, Hicks J, Ogg C, Williams DG. Adult-onset minimal change nephrotic syndrome:a long-term follow-up. Kidney Int 1986; 29: 1215-1223.
52. Korbet SM, Schwartz MM, Lewis EJ. Minimal-change glomerulopathy of adulthood. Am J Nephrol 1988; 8: 291-297.
53. Fujimoto S, Yamamoto Y, Hisanaga S, Morita S, Eto T, Tanaka K. Minimal change nephrotic syndrome in adults:response to corticosteroid therapy and frequency of relapse. Am J Kidney Dis 1991; 17: 687-692.
54. Mak SK, Short CD, Mallick NP. Long term outcome of adult-onset minimal change nephropathy. Nephrol Dialysis Transplant 1996; 11: 2192-2201.
55. Serkova N, Christians U. Transplantation:toxicokinetics and mechanisms of toxicity of cyclosporine and macrolides. Curr Opin Invest Drugs 2003; 4: 1287-1296.
56. Filler G. How should microemulsified cyclosporine A (Neoral®) therapy in patients with nephrotic syndrome be monitored? Nephrol Dial Transplant 2005; 20: 1032-1034.
57. Matsumoto H, Nakao T, Okada T, Nagaoka Y, Shino T, Yoshino M et al. Initial remission-inducing effect of very low-dose cyclosporine monotherapy for minimal-change nephrotic syndrome in Japanese adults. Clin Nephrol 2001; 55: 143-148.
58. Day CJ, Cockwell P, Lipkin GW, Savage CO, Howie AJ, Adu D. Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant 2002; 17: 2011-2013.
59. Choi MJ, Eustace JA, Gimenez LF, Atta MG, Scheel PJ, Sothinathan R et al. Mycophenolate mofetil for primary glomerular diseases. Kidney Int 2002; 61: 1098-1114.
60. Norona B, Valentin M, Gutierrez E, Praga M. Treatment of steroid-dependent minimal change nephrotic syndrome with mycophenolate mofetil. Nefrologia 2004; 24: 79-82. (In Spanish.)
61. Braden GL, Mulhern JG, O'Shea MH, Nash SV, Ucci AA, Germain MJ. Changing incidence of glomerular diseases in adults. Am J Kidney Dis 2000; 35: 878-883.
62. Dragovic D, Rosenstock JL, Wahl SJ, Panagopoulos G, DeVita MV, Miche-lis MF. Increasing incidence of focal segmental glomerulosclerosis and an examination of demographic patterns. Clin Nephrol 2005; 63: 1-7.
63. Crook ED, Habeeb D, Gowdy O, Nimmagadda S, Salem M. Effects of steroids in focal segmental glomerulosclerosis in a predominantly African-Americanpopulation. Am J Med Sci 2005; 330: 19-24.
64. Ahmed MS, Wong CF. Rituximab and nephrotic syndrome:a new therapeutic hope? Nephrol Dial Transplant 2008; 23: 11-17.
65. Deegens JK, Assmann KJ, Steenbergen EJ, Hilbrands LB, Gerlag PG, Jansen H et al. Idiopathic focal segmental glomerulosclerosis:a favourable prognosis in untreated patients? Neth J Med 2005; 63: 393-398.
66. Korbet S, Schwartz M, Lewis E. Primary focal segmental glomerulosclerosis:clinical course and response to therapy. Am J Kidney Dis 1994; 23: 773-783.
67. Korbet SM. Management of idiopathic nephrosis in adults, including steroid-resistant nephrosis. Curr Opin Nephrol Hypertens 1995; 4: 169-176.
68. Meyrier A. Treatment of focal segmental glomerulosclerosis. Expert Opin Pharmacother 2005; 6: 1539-1549.
69. Stirling CM, Mathieson P, Boulton-Jones JM, Feehally J, Jayne D, Murray HM et al. Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK units. Q J Med 2005; 98: 443-449.
70. Heering P, Braun N, Mullejans R, Ivens K, Zauner J, Funfstuck R et al. Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am J Kidney Dis 2004; 43: 10-18.
71. Martinelli R, Pereira LJ, Silva OMM, Okumura AS, Rocha H. Cyclophosphamide in the treatment of focal segmental glomerulosclerosis. Braz J Med Biol Res 2004; 37: 1365-1372.
72. Segarra A, Vila J, Pou L, Majo J, Arbos A, Quiles T et al. Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or-dependent idiopathic focal glomerulosclerosis:a preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant 2002; 17: 655-662.
73. Duncan N, Dhaygude A, Owen J, Cairns TD, Griffith M, LcLean AG et al. Treatment offocal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant 2004; 19: 3062-3067.
74. Voehringer M, Keller F. Effect of sirolimus on nephrotic syndrome and renal function in 7 patients with focal sclerosing glomerulonephritis. J Am Soc Nephrol 2004; 15: 555A.
75. Tumlin JA, Miller D, Near M, Selvaraj S, Hennigar R, Guasch A. A prospective, open-label trial of sirolimus in the treatment of focal seg-mentalglomerulonephritis. Clin J Am Soc Nephrol 2006; 1: 109-116.
76. Choi MJ, Eustace JA, Gimenez LF, Atta MG, Scheel PJ, Sothinathan R et al. Mycophenolate mofetil for primary glomerular diseases. Kidney Int 2002; 61: 1098-1114.
77. Cattran DC, Wang MM, Appel G, Matalon A, Briggs W. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004; 62: 405-411.
78. Segarra A, Amoedo ML, Martinez Garcia JM, Pons S, Praga M, Garcia EI et al. Efficacy and safety of 'rescue therapy' with MMF in resistant primary glomerulonephritis:a multicentre study. Nephrol Dial Transpl 2007; 22: 1351-1360.
79. Shalhoub RJ. Pathogenesis of lipoid nephrosis:a disorder of T cell function. Lancet 1974; ii:556-559.
80. Matalon A, Markowitz GS, Joseph RE, Cohen DJ, Saal SD, Kaplan B et al. Plasmapheresis treatment of recurrent FSGS in adult renal transplant recipients. Clin Nephrol 2001; 56: 271-278.
81. Davenport RD. Apheresis treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation:re-analysis of published case-reports and case-series. J Clin Apher 2001; 16: 175-178.
82. Shariatmadar S, Noto TA. Therapeutic plasma exchange in recurrent focal segmental glomerulosclerosis following transplantation. J Clin Apher 2002; 17: 78-83.
83. Otsubo S, Tanabe K, Shinmura H, Ishikawa N, Tokumoto T, Hattori M et al. Effect of post-transplant double filtration plasmapheresis on recurrent focal and segmental glomerulosclerosis in renal transplant recipients. Ther Apher Dial 2004; 8: 299-304.
84. Valdivia P, Gonzalez Roncero F, Gentil MA et al. Plasmapheresis for the prophylaxis and treatment of recurrent focal segmental glomerulosclerosis following renal transplant. Transplant Proc 2005; 37: 1473-1474.
85. Gohh RY, Yango AF, Morrissey PE, Monaco AP, Gautam A, Sharma M et al. Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant 2005; 5: 2907-2912.
86. Pardon A, Audard V, Caillard S, Moulin B, Desvaux D, Bentaari B et al. Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients. Nephrol Dial Transplant 2006; 21: 1053-1059.
87. Bosch T, Wendler T. Extracorporeal plasma treatment in primary and recurrent focal segmental glomerular sclerosis:a review. Ther Apher 2001; 5: 155-160.
88. Dantal J, Bigot E, Bogers W, Testa A, Kriaa F, Jacques Y et al. Effect of plasmaproteinadsorptioninkidney-transplantrecipientswithrecurrent nephrotic syndrome. N Engl J Med 1994; 330: 7-14.
89. Esnault VL, Besnier D, Testa A, Coville P, Simon P, Subra JF et al. Effect of protein A immunoadsorption in nephrotic syndrome of various etiologies. J Am Soc Nephrol 1999; 10: 2014-2017.
90. Nijland MJM. Fetal exposure to corticosteroids:how low can we go? J Physiol 2003; 549(1): 1.
91. Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapyduringpregnancy:ameta-analysis. Transplantation 2002; 71: 1051-1055.
92. Armenti GT. Immunosuppression and teratology:evolving guidelines. J Am Soc Nephrol 2004; 15: 2759-2760.
93. Armenti VT, Radomski JS, Moritz MJ, Gaughan WJ, McGrory CH, Coscia LA. Report from the National Transplantation Pregnancy Registry (NTPR):outcomes of pregnancyafter transplantation. Clin Transpl 2003; 2003: 131-141.